Biopharma executives face a daunting number of decisions daily as they address the challenges of bringing drugs—which may be unstable and unpredictable—to market. Perhaps the most important decision is selecting the biomanufacturing strategy that is the best fit for their organization.
View this webcast to hear industry experts discuss the benefits of having a flexible, multi-pronged approach, along with the pros and cons of outsourcing versus staying in-house for biologics drug-substance manufacturing.
Barry Rosenblatt, PhD, President, SME Biotech Consulting
Dave Kenyon, PhD, Vice President, Process Sciences, Patheon